Overview

Ocular Drug Delivery Technology Market is poised to value over USD 19 billion by 2027 end at a CAGR of over 6.8% during the forecast period 2020 to 2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Ocular Drug Delivery Technology Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Ocular Drug Delivery Technology Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Ocular Drug Delivery Technology Market:
• Ocular Therapeutix, Inc.
• Alimera Sciences
• Allergan, Plc
• Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Incorporated)
• EyeGate Pharma
• Envisia Therapeutics
• Clearside Biomedical, Inc.
• Graybug Vision Inc.
• Santen Pharmaceutical Co., Ltd
• Taiwan Liposome Company, Ltd
(Note: The list of the major players will be updated with the latest market scenario and trends)

Ocular Drug Delivery Technology Market Segmentation:
By Technology
• Topical
• Ocular Insert
   o Erodible
   o Non-Erodible
• Iontophoresis
• Intraocular Implants
   o Biodegradable
   o Non-Biodegradable
• In Situ Gel & Punctal Plugs
• Others
By Formulation Type
• Solution
• Suspension
• Emulsion
• Liposomes & Nanoparticles
• Ointment
By Disease Type
• Glaucoma
• Macular Degeneration
• Diabetic Retinopathy
• Cataract
• Diabetic Macular Edema
• Dry Eye Syndrome
• Others
By End User
• Hospitals
• Ambulatory Surgical centers
• Ophthalmic Clinics
• Homecare Settings
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Ocular Drug Delivery Technology Market By Technology, By Formulation Type, By Disease Type, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Ocular Drug Delivery Technology Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Ocular Drug Delivery Technology Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Ocular Drug Delivery Technology Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals and Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Ocular Drug Delivery Technology Market, By Technology Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Topical
  7.2. Ocular Insert
         7.2.1. Erodible
         7.2.1.Non-Erodible
  7.3. Iontophoresis
  7.4. Intraocular Implants
         7.4.1. Biodegradable
         7.4.2. Non-Biodegradable
  7.5. In Situ Gel & Punctal Plugs
  7.6. Others

8. Global Ocular Drug Delivery Technology Market, By Formulation Type Historical Analysis and Forecast 2020-2027 (USD Million)
  8.1. Solution
  8.2. Suspension
  8.3. Emulsion
  8.4. Liposomes & Nanoparticles
  8.5. Ointment
9. Global Ocular Drug Delivery Technology Market, By Disease Type Historical Analysis and Forecast 2020-2027 (USD Million)
  9.1. Glaucoma
  9.2. Macular Degeneration
  9.3. Diabetic Retinopathy
  9.4. Cataract
  9.5. Diabetic Macular Edema
  9.6. Dry Eye Syndrome
  9.7. Others

10. Global Ocular Drug Delivery Technology Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
  10.1. Hospital
  10.2. Ambulatory Surgical centers
  10.3. Ophthalmic Clinics
  10.4. Homecare Settings

11. North America Ocular Drug Delivery Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
  11.1. Introduction
  11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
       11.2.1. U.S.A
       11.2.2. Canada
       11.2.3. Mexico
  11.3. Market Size (USD Million) Forecast for North America 2020-2027

12. Latin America Ocular Drug Delivery Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         12.2.1. Brazil
         12.2.2. Venezuela
         12.2.3. Argentina
         12.2.4. Rest of Latin America
   12.3. Market Size (USD Million) Forecast for Latin America 2020-2027

13. Europe Ocular Drug Delivery Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         13.2.1. Germany
         13.2.2. U.K        
         13.2.3. France
         13.2.4. Italy
         13.2.5. Spain
         13.2.6. Russia
         13.2.7. Poland
         13.2.8. Rest of Europe
   13.3. Market Size (USD Million) Forecast for Europe 2020-2027

14. Asia Pacific Ocular Drug Delivery Technology Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         14.2.1. Japan
         14.2.2. China
         14.2.3. India
         14.2.4. Australia and New Zealand
         14.2.5. ASEAN
         14.2.6. Rest of Asia Pacific
   14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   15.1. Introduction
   15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         15.2.1. Saudi Arabia
         15.2.2. UAE
         15.2.3. South Africa
         15.2.4. Egypt
   15.3. Market Size (USD Million) Forecast for MEA 2020-2027

16. Market Share Analysis and Competitive Landscape  
   16.1. Global Landscape - Key Players, Revenue and Presence
   16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   16.3. Global Emerging Companies
   16.4. North America - Market Share Analysis and Key Regional Players
   16.5. Europe - Market Share Analysis and Key Regional Players
   16.6. Asia Pacific - Market Share Analysis and Key Regional Players
   16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   17.1. Ocular Therapeutix, Inc.
         17.1.1. Company Overview
         17.1.2. Product Portfolio
         17.1.3. SWOT Analysis
         17.1.4. Financial Overview
         17.1.5. Strategic Overview
   17.2. Alimera Sciences
         17.2.1. Company Overview
         17.2.2. Product Portfolio
         17.2.3. SWOT Analysis
         17.2.4. Financial Overview
         17.2.5. Strategic Overview
   17.3. Allergan, Plc
         17.3.1. Company Overview
         17.3.2. Product Portfolio
         17.3.3. SWOT Analysis
         17.3.4. Financial Overview
         17.3.5. Strategic Overview
   17.4. Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Incorporated)
         17.4.1. Company Overview
         17.4.2. Product Portfolio
         17.4.3. SWOT Analysis
         17.4.4. Financial Overview
         17.4.5. Strategic Overview
    17.5 EyeGate Pharma
         17.5.1. Company Overview
         17.5.2. Product Portfolio
         17.5.3. SWOT Analysis
         17.5.4. Financial Overview
         17.5.5. Strategic Overview          
    17.6 Envisia Therapeutics
         17.6.1. Company Overview
         17.6.2. Product Portfolio
         17.6.3. SWOT Analysis
         17.6.4. Financial Overview
         17.6.5. Strategic Overview      
   17.7. Clearside Biomedical, Inc.
         17.7.1. Company Overview
         17.7.2. Product Portfolio
         17.7.3. SWOT Analysis
         17.7.4. Financial Overview
         17.7.5. Strategic Overview
   17.8. Graybug Vision Inc.
         17.8.1. Company Overview
         17.8.2. Product Portfolio
         17.8.3. SWOT Analysis
         17.8.4. Financial Overview
         17.8.5. Strategic Overview
   17.9. Santen Pharmaceutical Co., Ltd.
         17.9.1. Company Overview
         17.9.2. Product Portfolio
         17.9.3. SWOT Analysis
         17.9.4. Financial Overview
         17.9.5. Strategic Overview
  17.10. Taiwan Liposome Company, Ltd
         17.10.1. Company Overview
         17.10.2. Product Portfolio
         17.10.3. SWOT Analysis
         17.10.4. Financial Overview
         17.10.5. Strategic Overview

18. Pre and Post COVID-19 Impact
   18.1. Positive influence on the healthcare industry
   18.2. The financial disruption of the manufacturing sector
   18.3. Impact of COVID-19 on emerging companies
   18.4. Significant mandates in the healthcare regulations initiated by administrations
   18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures